Table 5.
Univariate analysis for overall survival, progression-free survival and locoregional control.
| Variable | OS | PFS | LRC | |||
|---|---|---|---|---|---|---|
| HR (95% CI) |
p | HR (95% CI) |
p | HR (95% CI) |
p | |
| rT stage (4 vs. 0–3) |
2.044 (1.157–3.612) |
.014 | 2.164 (1.234–3.795) |
.007 | 2.211 (1.134–4.312) |
.020 |
| rN stage (2–3 vs. 0–1) |
1.192 (0.672–2.114) |
.549 | 1.378 (0.786–2.415) |
.263 | 1.645 (0.846–3.201) |
.143 |
| Disease-free interval (>24 vs. ≤24 months) |
0.572 (0.325–1.008) |
.053 | 0.630 (0.360–1.100) |
.104 | 0.510 (0.256–1.016) |
.056 |
| Age (>60 vs. ≤60 years) |
0.607 (0.345–1.068) |
.084 | 0.541 (0.310–0.945) |
.031 | 0.365 (0.181–0.733) |
.005 |
| Charlson comorbidity (≥3 vs. 1–2) |
0.950 (0.539–1.674) |
.859 | 0.884 (0.509–1.538) |
.663 | 0.974 (0.502–1.888) |
.938 |
| Baseline dysphagia (Grade 3–4 vs. 0–2) |
2.399 (1.280–4.495) |
.006 | 1.763 (0.973–3.194) |
.061 | 1.507 (0.743–3.054) |
.255 |
| Surgery (Yes vs. no) |
1.159 (0.667–2.012) |
.600 | 0.956 (0.556–1.642) |
.869 | 0.904 (0.469–1.742) |
.763 |
| Chemotherapy | ||||||
| Ind. but not adm. | 1.000 | .002 | 1.000 | .004 | 1.000 | .022 |
| Early terminated | 0.934 (0.442–1.974) |
.857 | 0.927 (0.453–1.898) |
.836 | 0.911 (0.389–2.133) |
.831 |
| Adm. as planned | 0.317 (0.148–0.680) |
.003 | 0.339 (0.165–0.700) |
.003 | 0.336 (0.144–0.785) |
.012 |
| Re-RT dose (60 vs. <60 Gy) |
0.296 (0.161–0.543) |
<.001 | 0.369 (0.206–0.661) |
<.001 | 0.609 (0.291–1.272) |
.187 |
OS, overall survival; PFS, progression-free survival; LRC, locoregional control; UVA, univariate analysis; HR, hazards ratio; CI, confidence interval; SP, second primary; LRR, locoregional recurrence; Ind., indicated; Adm., administered; re-RT, re-irradiation.